Global Autoimmune Drugs Market 2016-2020 - Loss of Patent Exclusivity of Branded Therapies a Key Challenge

Mar 25, 2016, 08:10 ET from Research and Markets

DUBLIN, March 25, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Autoimmune Drugs Market 2016-2020" report to their offering.

     (Logo: )

The analysts forecast the global autoimmune diseases drugs market to grow at a CAGR of 5.57% during the period 2016-2020

Autoimmune diseases are immunological disorders that occur when the immune system attacks and destroys healthy tissues in the body rather than foreign bodies, causing significant pain, inflammation, and organ damage. These diseases can affect the nervous system, cardiovascular system, and musculoskeletal system or individual organs, including the skin, lungs, kidneys, glands, and joints.

The awareness of autoimmune diseases among the general public is low. Many physicians are also poorly trained in this area. To overcome these drawbacks, a new specialty Autoimmunologist was designed to lead physicians from different disciplines. In addition, the Prevention, Awareness, and Research of Autoimmune Diseases Act (AARDA) provided funding of up to $18 million to create awareness for these diseases.

Further, the report states that patent expiries result in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales.

Key vendors: 

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen
  • F. Hoffmann-La Roche
  • Johnson & Johnson Private Limited
  • Pfizer Inc.

Key questions answered in this report: 

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Key Topics Covered:

PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Market segmentation by type of disease 
PART 09: Market segmentation by mechanism of action
PART 10: Market segmentation by drug class
PART 11: Market segmentation by type of molecule
PART 12: Market segmentation by ROA
PART 13: Market segmentation by dosage form
PART 14: Geographical segmentation
PART 15: Market drivers
PART 16: Impact of drivers
PART 17: Market challenges
PART 18: Impact of drivers and challenges
PART 19: Market trends
PART 20: Vendor landscape

For more information visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets